POLYMED Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹494 Cr
verified against source
Revenue YoY
16.4%
reported change
EBITDA
₹119 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Poly Medicure delivered Q3 FY26 consolidated revenue of ₹494 crore (up 16.4% YoY), driven primarily by acquisitions contributing ₹48-49 crore. The standalone operating EBITDA margin of 26.8% remains robust at the higher end of annual guidance. The company completed acquisitions of Pentrocare (cardiology) and CTF Group (orthopedics) to transition into high-complexity, high-growth segments. Domestic business grew 16.2% YoY with private market expansion of 22.5%, while international revenue of ₹342 crore grew 16.6% YoY with Europe delivering 25.7% growth. The company faces headwinds from Chinese dumping in renal and infusion segments, with dialysis machine sales tracking to 450 units (below 500-600 guidance). FY27 guidance includes domestic growth of ~25% and international growth of 12-15%, with overall 20% revenue growth targeted. Key risks include intense Chinese competition in export markets, margin pressure from newly acquired entities operating at lower margins, and delayed government dialysis contracts.
Colored figures show movement against the previous available record.
Guidance to track
- Domestic private business (88% of domestic) growing 23% this year with new hospital contracts and expansion into cardiology/critical care driving higher growth next year.
- International organic business currently flat; growth driven by new EU-MDR approvals (15+ products in pipeline), NHS UK contracts, and new European customers starting April.
- Q4 revenue expected at approximately ₹530 crore vs. Q3's ₹493 crore; H2 revenue expected 20% higher than H1 (₹847 crore vs. ₹847 crore approximately).
- On standalone basis, EBITDA margin at higher end of annual guidance at 26.6-26.8% for 9 months; expected to be maintained for rest of FY26.
Risks flagged
- Chinese companies using FDA 510(k) route to import products at zero duty into India, severely impacting domestic renal business. Company has raised this concern with government officials. Dialysis machine sales tracking 450 vs. initial 500-600 guidance.
- International organic business excluding acquisitions is currently flattish due to European market weakness, MDR transition delays, and NHS contract deferrals. China dumping also affecting export markets globally.
- Company strategically reducing government business exposure (from 10-12% to 6-7%) due to lower prices and payment delays, though this impacts overall growth trajectory and market reach.
- Newly acquired Pentrocare and CTF Group currently operating at 50-60% capacity utilization with lower EBITDA margins, causing consolidated margins to be lower than standalone. Full impact will be visible in FY27.
Key quotes
- If I need to compete with China, I have to be 10% cheaper than China, if I have to break that market. Now that is not happening because China's volume numbers are very different than India. So how do we win the market? We have to reorient ourselves toward clinical side of the business.
- We are moving from selling a product of ₹15 to selling a product of ₹1.5 lakh. So we need a lot of skill sets, and that's what we are doing right now.
- None of the industries have survived in India when they have zero duty with Chinese manufacturing. Today on iPhones we have 20% duty, even cars have 100% duty. So I think fundamentally, government will have to take corrective steps.
Research modules